Compare NSSC & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSSC | PRAX |
|---|---|---|
| Founded | 1969 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 9.6B |
| IPO Year | 1994 | 2020 |
| Metric | NSSC | PRAX |
|---|---|---|
| Price | $46.20 | $337.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 15 |
| Target Price | $48.17 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 545.6K | 386.6K |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.29% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $181,621,000.00 | N/A |
| Revenue This Year | $13.47 | N/A |
| Revenue Next Year | $9.75 | $1,840.20 |
| P/E Ratio | $64.53 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.63 | $26.70 |
| 52 Week High | $47.61 | $354.87 |
| Indicator | NSSC | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 64.74 | 59.96 |
| Support Level | $41.96 | $290.36 |
| Resistance Level | $47.61 | N/A |
| Average True Range (ATR) | 1.68 | 18.81 |
| MACD | 0.29 | -0.01 |
| Stochastic Oscillator | 82.80 | 71.32 |
NAPCO Security Technologies Inc manufactures security products, encompassing access control systems, door-locking products, intrusion and fire alarm systems and video surveillance products. Its products are used for various applications which includes alarm systems like automatic communicators, combination control panels/digital communicators and digital keypad systems, fire alarm control panel and area detectors mainly used for commercial, residential, institutional, industrial and governmental uses. Geographically, the company derives a majority of its revenue from the United States.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.